Skip to main content
Premium Trial:

Request an Annual Quote

AutoGenomics Withdraws IPO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – AutoGenomics has pulled its initial public offering.

On Wednesday, the Vista, Calif.-based company filed papers with the US Securities and Exchange Commission for the "immediate withdrawal" of its registration statement for its IPO.

No reason was given for the decision.

The molecular diagnostics firm filed for its IPO nearly three years ago, and last summer amended its S-1 filing, but never offered a price range for its shares in a potential offering, although it said that the maximum aggregate offering price was $86.3 million. Its CEO, Fareed Kureshy, told GenomeWeb Daily News last year that AutoGenomics had no intention of pulling its IPO but had determined along with the underwriters for the IPO that there was no clear market, or after-market for his company.

As a result, the company was waiting "for the right opportunity in the marketplace so that there is a strong demand" for the IPO, Kureshy said.

The underwriters on the offering were Jefferies & Co., R.W. Baird, and Stifel Nicolaus Weisel.

In the past year, other life science tools firms, such as Pacific Biosciences and Complete Genomics, have successfully completed their IPOs, but the market remains a challenging one. In addition to AutoGenomics, other firms that have pulled their IPOs recently include Atossa Genetics and Rules-Based Medicine — though RBM is now being acquired by Myriad Genetics in an $80 million deal.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.